Background
Chronic obstructive pulmonary disease (COPD) is a leading cause of mortality and morbidity worldwide. 1 It is characterized by progressive airflow limitation, and COPD severity is assessed using forced expiratory volume in 1 s (FEV 1 ). 2 However FEV 1 is poorly correlated with clinical manifestations of the disease 3 and standardized measurement of patient-related outcomes (e.g., health status) has been proposed for more comprehensive assessment of disease severity. 4 Health-related quality of life (HRQoL) measurement using validated questionnaires provides a standardized method for assessing the impact of disease on patients' daily lives, activity and well-being. 4 Generic questionnaires are designed to assess health status irrespective of underlying disease, while disease-specific questionnaires tend to be more sensitive to change. The disease-specific St. George's Respiratory Questionnaire (SGRQ) 5 is the most frequently used questionnaire for assessing HRQoL in COPD subjects. Large epidemiological studies have used SGRQ and have demonstrated that HRQoL was impaired in COPD subjects, 6 and was independently associated with hospital readmission 7 and mortality. 8 Comorbidities, defined as other chronic diseases associated with COPD (irrespective of the nature-causal or notof their link with the disease), are frequently present in COPD patients and their impact is increasingly recognized. 9 High rates of cardiovascular diseases, diabetes, and mood disorders (e.g., anxiety and depression) were reported in COPD patients. 9, 10 These comorbidities were reported to increase the risk of mortality and hospitalizations in COPD patients, 11, 12 and they exponentially increased the costs of treatment. 13 Determinants of HRQoL impairment in COPD patients, as measured by the SGRQ, have been the subject of several studies. Respiratory features, including the severity of airflow limitation, 14 dyspnea 15 and repeated exacerbations 16 were reported to be independently associated with impaired HRQoL. Recent studies have further suggested that COPD subjects with anxiety and/or depression had impaired HRQoL, 12, 17, 18 but only scarce data exist on the impact of other comorbidities (e.g., cardiovascular diseases and diabetes) on HRQoL. In previous studies, subjects with severe comorbidities were either excluded, 19 not reported 20 or examined using the rather imprecise Charlson index. 21, 22 In a pioneer study published in 1997, Ferrer et al. found that comorbid conditions partly influenced SGRQ scores 23 : the relationship was clear in mild COPD cases but absent in those with severe airflow obstruction. However, comorbidities were reported by organ involvement (e.g., "heart problems") and the relative contribution of individual comorbidities was not reported. Therefore, the contribution of comorbidities to the HRQoL impairment found in COPD patients has not been clearly established.
In the present study, the relation between physiciandiagnosed comorbidities and SGRQ scores was analyzed in patients included in the INITIATIVES BPCO cohort. 24 The main goal of these analyses was to evaluate the independent contribution of comorbidities e including mood disorders, metabolic and cardiovascular comorbidities e to SGRQ scores, in the presence of known respiratory factors associated with HRQoL impairment such as dyspnea and exacerbation frequency.
Methods
The INITIATIVES BPCO cohort COPD subjects included in the present analysis were recruited in the INITIATIVES BPCO cohort between January 2005 and August 2009. INITIATIVES BPCO cohort is a realworld cohort of spirometry-diagnosed COPD patients identified in university hospitals located throughout France. Data are recorded in a standardized case report form but, due to the real-world nature of patient's care, datasets do not have to be complete to include a patient. Only demographic characteristics and spirometry are mandatory. Detailed information about this cohort can be found in a previous report. 24 Respiratory physicians prospectively recruited subjects in stable condition (no history of exacerbation requiring medical treatment during the previous 4 weeks) with a diagnosis of COPD based on a postbronchodilator FEV 1 /FVC ratio <70%. 2 The study was approved by the Ethics Committee of Versailles (France) and all subjects provided written informed consent.
Data collection
The standardized characterization process covered demographic data, cumulative tobacco smoking, and COPD characteristics (including symptoms and spirometry) in stable condition. Pulmonary function tests were performed according to international standards. 25 Severity of airflow obstruction was evaluated according to GOLD classification. 2 The number of self-reported acute exacerbations of COPD during the previous year was determined. Physiciandiagnosed cardiovascular comorbidities (including congestive heart failure, coronary artery disease, and hypertension) were identified from the patient files. Diabetes mellitus was considered present when patients were treated with insulin or oral antidiabetic drugs. Malnutrition was defined as a body mass index (BMI) 18.5 kg/m 2 and obesity as a BMI >30 kg/m 2 . 26 Dyspnea was assessed using the modified MRC scale. 27 The hospital anxiety and depression (HAD) scale was used to examine mood disorders. This 14-item self-questionnaire has two 7-item subscales for anxiety (HAD-A) and depression (HAD-D). A score of 10 or higher on either subscale is closely associated with the presence of the corresponding mood disorder. 12 Health-related quality of life was evaluated using the SGRQ. 5 For the purpose of these analyses only subjects with complete data for comorbidities (coronary artery disease, chronic heart failure, diabetes, hypertension), mMRC, hospital anxiety and depression (HAD) scale and SGRQ score were selected.
Statistical analysis
Data are presented as median [interquartile range; IQR] or n (%). Univariate associations between SGRQ scores and other variables were analyzed using Kendall tau b correlations and Wilcoxon's test for continuous and categorical variables, respectively. Stepwise forward and backward multiple regression analyses were performed to examine determinants of SGRQ total score. In these analyses, comorbidities were included as individual variables. Exacerbations were included either as a whole or as severe exacerbations only (i.e., exacerbations requiring hospitalization). Because we found that low BMI, but not obesity, was associated with increased SGRQ total score in the univariate analysis, we analyzed BMI as a categorical variable (low vs. normal þ increased BMI). Similarly, determinants of SGRQ activity, symptom and impact scores were determined using stepwise forward and backward multiple regression analyses. All covariates with a P-value <0.15 were entered into the multivariate regression models, and successively excluded if they were not associated with the outcome (P < 0.10). Analyses were performed using the SAS Ò 9.2 statistical software.
Results

Patients
The INITIATIVES BPCO cohort contained data on 633 COPD subjects. Data on SGRQ scores were missing in 174 subjects and evaluation of mood disorders by the HAD scale was missing in 210 subjects. Comparison of the 326 (51.5%) subjects with complete data (see Methods) to the 307 (48.5%) subjects with incomplete data is shown in Table 1 . Subjects with complete data had a trend toward higher rates of chronic heart failure (15% vs. 11%, P Z 0.08), and toward a higher proportion of women (23 vs. 18%, P Z 0.07). No other differences were found between included and excluded subjects. Among the 326 subjects included in the analyses, all GOLD stages were represented with 21 (6.4%) patients in GOLD I, 135 (41.4%) patients in GOLD II, 110 patients (33.7%) in GOLD III and 60 patients (18.5%) in GOLD IV. Low BMI ( 18.5 kg/m 2 ) was found in 36 subjects (11%) and obesity (BMI >30 kg/m 2 ) in 52 subjects (16%). Previously diagnosed comorbidities were highly prevalent (see Table  1 ): only 115 patients (35%) had no comorbidities, whereas 171 patients (53%) had 1 or 2 comorbidities and 40 patients (12%) had 3 or more comorbidities. At least one cardiovascular comorbidity (defined as hypertension, coronary artery disease, or chronic heart failure) was present in 158 patients (48%). No significant difference was found among GOLD stages for cardiovascular comorbidities, anxiety or depression (not shown). Correlation of SGRQ total score with FEV 1 % pred and GOLD stages is presented in Fig. 1 . SGRQ total scores also increased with exacerbation frequency and more severe dyspnea (see Table 2 ). Median [IQR] SGRQ total scores were 40 [27e58] in subjects without hospitalization for exacerbation in the previous year (n Z 243), 46 [35e62] in subjects who had one hospitalization (n Z 50) and 63
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[51e71] in subjects with !2 hospitalizations (n Z 33; all comparisons, P < 0.001). The relationship between comorbidities and SGRQ total scores is summarized in Fig. 2 and Table 3 . Subjects with low BMI ( 18.5 kg/m 2 ), anxiety, or depression had higher SGRQ total scores, whereas those with coronary artery disease, chronic heart failure and previous venous thromboembolism had no significant difference in SGRQ total scores. No significant increase in SGRQ total score was found in subjects with cardiovascular comorbidities or with multiple comorbidities (see Fig. 2 ). Univariate determinants of SGRQ activity, impact and symptom scores are described in Tables 2 and 3 .
Multivariate determinants of SGRQ scores
Results of the stepwise multiple regressions for SGRQ total score and for SGRQ activity, impact and symptom scores are shown in Table 4 . Major (as indicated by high R 2 values) determinants of SGRQ total score included dyspnea and exacerbations/patient/year (but not hospitalizations/ patient/yr). In the presence of these variables, the most important contributor to SGRQ total score was depression. Low BMI, coronary artery disease and FEV 1 (% predicted) were also independently associated with impaired HRQoL, but their contribution was modest (as shown by low R 2 values). Fig. 3 summarizes the factors independently associated with SGRQ total, symptoms, activity and impact scores.
Discussion
The present study confirmed that dyspnea and exacerbations, but not airflow limitation, are major determinants of SGRQ total score in a real-life cohort of stable COPD patients. In the presence of these variables, depression was the most important variable associated with SGRQ total score. Although low BMI and coronary artery disease also affected HRQoL, their impact was only modest. Other cardiovascular comorbidities, obesity and diabetes had no significant impact.
The weak negative correlation between FEV 1 % predicted and SGRQ total score confirmed that HRQoL is worsening with increasing spirometric severity. 14, 28 However, SGRQ total scores were highly variable within each GOLD stage, confirming recently published data. 3 Multivariate analysis revealed that the most important determinants of SGRQ total scores were dyspnea and exacerbations. Although subjects with repeated hospitalizations had worse HRQoL, repeated hospitalizations were not retained in our multivariate model, presumably because (i) subjects with repeated hospitalizations also experienced multiple nonhospitalized exacerbations, and (ii) non-hospitalized exacerbations were more numerous than those requiring hospitalization. These findings are consistent with previous reports showing that the severity of dyspnea is more closely associated with SGRQ total score than the level of FEV 1 impairment 15, 27 and that higher exacerbation frequency is associated with worse HRQoL independently of the level of dyspnea. 16 The major focus of this study was the contribution of comorbidities to HRQoL impairment, as examined using the 12 The latter results were obtained when including subjects with suspected anxiety and/or depression (HAD subscale values !8), and our study extend and reinforce these data by showing that comparable results are obtained when the analyses are limited to subjects in whom depression was highly probable (HAD subscale values !10).
The presence of cardiovascular comorbidities or diabetes was not associated with significantly higher SGRQ total scores in univariate analysis: although coronary artery disease was found to contribute independently to HRQoL in multivariate analysis integrating respiratory determinant of SGRQ total scores, its contribution was only modest. Further, patients with multiple comorbidities had no significant increase in SGRQ total score. These results are in contradiction with those obtained by Balcells et al., who found that the presence of comorbidities, as assessed using the Charlson index, was associated with increased SGRQ scores in a cohort of stable COPD subjects. 22 de Torres et al. also reported that the Charlson index was independently associated with SGRQ total score in male, but not in female, with COPD. 21 The Charlson index is an imprecise descriptor of comorbidities in COPD subjects, limiting the comparability of these data to what is reported here. Further, these studies did not include data on exacerbations, 21 ,22 a major determinant of SGRQ. In a recent report that studied a large number of subjects (n Z 1817 subjects) in primary care across Europe, the authors reported that patients with !3 comorbidities had a significantly worse SGRQ total score vs. patients with 1e2 comorbidities or no comorbid condition. 6 In the latter study, subjects with cardiovascular comorbidities had only a small increase in SGRQ total scores vs. subjects with no cardiovascular comorbidities. The difference was statistically significant, but was less than the minimal clinically important difference (MCID). 6 The present results confirm The present study has several strengths. Data on comorbidities were prospectively recorded and were based on physician-diagnosed comorbidities for cardiovascular comorbidities and diabetes, and systematic assessment of anxiety and depression using a validated questionnaire (HAD scale). The cut-off values (!10) for each HAD subscale were chosen to select subjects in whom the diagnosis of anxiety and/or depression was highly probable. 30 Some limitations also have to be recognized. Our patients were recruited in pulmonary clinics of university hospitals and therefore may not represent the COPD population at large. However, these patients had a wide range of airflow limitation and our subjects in GOLD stage 2, 3, and 4 had median [IQR] values of SGRQ total scores that were remarkably comparable with those found by Jones et al. in a large sample of COPD patients recruited in primary care across Europe. 6 HRQoL was measured using SGRQ, but no generic HRQoL questionnaire was utilized. In a recent study, the authors suggested that SGRQ cannot capture all aspects of health status in COPD patients, 31 and the use of a generic questionnaire may have resulted in different results. However, when designing the cohort in the early 2000' it was pragmatically decided to limit recorded HRQoL evaluation to the SGRQ, which is often the only questionnaire used in cohort studies and clinical trials. Further studies using multiple questionnaires, including generic HRQoL questionnaires and newly developed short COPDspecific questionnaires (e.g., CAT, 32 VSRQ 33 and CCQ 34 ), should be planned to fully understand the impact of comorbidities in this context. Some frequent comorbidities (e.g., osteoporosis, anemia, lung cancer, renal failure and atrial fibrillation) were not assessed in this study; thus, we were unable to determine their impact on SGRQ score. Because our database was not designed to match individual comorbidities with their treatments, we were unable to evaluate whether subjects were receiving appropriate treatments for comorbidities. In addition, it must be outlined that many comorbidities (e.g., left heart failure, 35 osteoporosis 36 ) often remain underdiagnosed; the possible impact of such undiagnosed comorbidities on HRQoL will require further studies.
Improvement of health status is one of the major goals of the treatment in COPD subjects. 2 Our study confirms that dyspnea and exacerbations are important targets for improving HRQoL in COPD subjects. These results are consistent with data showing that pharmacologic interventions that improve dyspnea and reduce exacerbations (e.g., long-acting bronchodilators alone or in combination with inhaled corticosteroids 37, 38 ) also improve HRQoL. Pulmonary rehabilitation, which improves dyspnea, decreases exacerbations and depression 39 and is associated with weight gain when combined with integrated nutritional program, 40 also improves HRQoL. Our results also Figure 3 Schematic representation of independent determinants of SGRQ activity, impact and symptom scores. Each score is represented by a circle surrounding the variables that were independently associated with this score in multiple stepwise regression analysis. Variables in bold were independent determinants of SGRQ total score. Variables outside of the circles were not associated with SGRQ scores.
reinforce the hypothesis that treatment of depression may result in improvement of HRQoL in COPD subjects. 10 They concur with recent data from von Leupoldt et al. who reported that, in COPD patients undergoing pulmonary rehabilitation, depression and anxiety are associated with poorer HRQoL and increased symptoms, both at baseline and over the course of rehabilitation. These findings led the authors to suggest that their early diagnosis and treatment may provide clinical benefits in these patients. 41 Because the present data was obtained in a cross-sectional design we could not exclude reverse causation between poor HRQoL and mental comorbidities, confirmation for this concept will require appropriate clinical trials.
Conclusions
In conclusion, we found that in the presence of dyspnea and exacerbations, depression is the most important contributor to HRQoL impairment measured by SGRQ in COPD subjects, whereas other comorbidities and FEV 1 have only limited impact. These data suggest that, although the SGRQ is of great value for evaluating the impact of COPD on HRQoL, additional instruments should be employed to measure the impact of co-existing non-communicable chronic diseases in patients with COPD.
